AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Insider Transactions Reported | Sight Sciences(SGHT)saw insider trading activity on 6/3/2025
ByAinvest
Wednesday, Jun 4, 2025 12:00 am ET1min read
Sight Sciences(SGHT) saw insider trading activity on 6/3/2025, there were 3 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 6/3/2025 | -- | Encrantz Staffan | Buy | 25230 | 3.97 | 100.09k |
| 6/3/2025 | -- | Encrantz Staffan | Buy | 42753 | 3.67 | 156.9k |
| 6/3/2025 | -- | Encrantz Staffan | Buy | 30799 | 3.88 | 119.44k |
| 5/29/2025 | -- | Encrantz Staffan | Buy | 26715 | 3.52 | 93.93k |
| 5/29/2025 | -- | Encrantz Staffan | Buy | 41346 | 3.44 | 142.06k |
| 5/29/2025 | -- | Encrantz Staffan | Buy | 60128 | 3.59 | 215.74k |
| 5/21/2025 | Chief Financial Officer | Bauerlein Alison | Sell | 13066 | 3.48 | 45.43k |
| 5/21/2025 | Chief Commercial Officer | Link Matthew | Buy | 6631 | 3.02 | 20.01k |
| 5/21/2025 | EVP, Research & Development | Raheja Manohar K. | Buy | 12767 | 3.02 | 38.53k |
| 4/3/2025 | President and CEO | Badawi Paul | Sell | 24174 | 2.30 | 55.67k |
[Company Profile]
Sight Sciences, Inc., was incorporated in Delaware in February 2010. The Company is an ophthalmic medical device company focused on the development and commercialization of surgical and non-surgical technologies for the treatment of common eye diseases. The company's business philosophy is based on the following principles: a comprehensive understanding of disease physiology; the development of transformative technologies designed to protect, protect and restore the natural physiological functions of diseased eyes; the development and marketing of products with proven clinical evidence that achieve effectiveness over current treatment models while minimizing complications or side effects; and the provision of intuitive, patient-friendly interventional solutions for ophthalmologists and optometrists; And provide compelling economic value to all stakeholders, including patients, providers and third-party payers such as health insurance companies and commercial insurance companies.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet